Bristol Myers Squibb Partners with Immunai to Deploy AI for Immune Response Analysis in Clinical Trials
核心洞察
Bristol Myers Squibb (搜索) has signed an agreement with AI biotechnology company Immunai (搜索) to analyze high-dimensional immune data from clinical studies using the AMICA-OS (搜索) platform.
The collaboration aims to decode patient immune responses and treatment variability to support clinical decision-making and drug development in immunology programs.
Immunai (搜索)'s AI-powered system will examine single-cell immune data to clarify mechanisms of action, identify biomarkers, and enable patient stratification across development stages.
Bristol Myers Squibb (搜索) has entered into a strategic agreement with artificial intelligence biotechnology company Immunai (搜索) to leverage advanced AI-powered immune data analysis in support of the pharmaceutical giant's clinical development programs. The collaboration will deploy Immunai's AMICA-OS (搜索) operating system to analyze complex immune datasets generated during Bristol Myers Squibb's clinical studies.
AI-Driven Immune System Mapping
Under the partnership, Immunai (搜索) will apply its AI-powered platform to examine high-dimensional immune data at scale, with the goal of deepening understanding of patient immune responses and variability in treatment outcomes. The analysis will utilize Immunai's immune system (搜索) AI models and underlying infrastructure to examine single-cell immune data, focusing on clarifying immune-driven mechanisms of action, supporting patient stratification, and identifying biomarkers.
"Understanding the immune system (搜索) at the level required to guide clinical development remains one of the most complex challenges in drug development," said Noam Solomon, Immunai (搜索)'s CEO. He emphasized that the collaboration with Bristol Myers Squibb (搜索) would focus on translating complex immune data into insights that could support decision-making in clinical programs.
Strategic Focus on Clinical Decision-Making
Bryan Campbell, Senior Vice President and Head of Drug Development Strategy and Innovation at Bristol Myers Squibb (搜索), highlighted the company's commitment to leveraging innovative approaches that deepen understanding of patient biology and treatment response. "The work with Immunai (搜索) would enable advanced AI technologies to generate meaningful immune insights from clinical data," Campbell stated.
The collaboration reflects a broader trend among large pharmaceutical companies toward using artificial intelligence not for direct drug discovery, but to extract clearer biological meaning from the vast and complex datasets generated during clinical trials, particularly in immunology where patient responses can differ widely even within the same disease category.
Expanding Industry Partnerships
Immunai (搜索) has been actively expanding its pharmaceutical industry partnerships. In September 2024, the company announced a multi-year collaboration with AstraZeneca to apply its platform and machine learning to oncology trials, beginning with an $18 million initial phase and an option to expand to an $85 million collaboration. In November 2024, Immunai unveiled a separate multi-year partnership with Teva (搜索) focused on immunology and immuno-oncology research.
The company has also strengthened its leadership team with senior pharmaceutical expertise. In March 2025, former Pfizer chief scientist Mikael Dolsten joined Immunai (搜索)'s board to support the integration of AI-driven immunology in drug development.
Platform Technology and Capabilities
Immunai (搜索)'s platform combines single-cell genomics with machine learning to map and decode the immune system (搜索) for drug development applications. The stated objectives of the Bristol Myers Squibb (搜索) collaboration include enabling more data-informed development decisions across various stages of clinical programs.
The companies indicated that the collaboration could expand to additional programs if the initial effort proves successful, suggesting potential for broader application of AI-driven immune analysis across Bristol Myers Squibb (搜索)'s development portfolio.